TABLE 2.
Baseline Characteristics of 76 Patients With PSC Included in the Study
| Characteristic | PSC (n = 76) | |
|---|---|---|
| Male sex | 51 | (67) |
| Age (years) | 44 | (31‐56) |
| PSC duration (years) | 8 | (4‐12) |
| PSC disease distribution | ||
| Intrahepatic + extrahepatic | 41 | (54) |
| Intrahepatic only | 35 | (46) |
| On UDCA therapy | 42 | (55) |
| IBD present | 57 | (75) |
| IBD phenotype | ||
| Ulcerative colitis | 42 | (55) |
| Crohn’s | 8 | (11) |
| Unspecified | 7 | (9) |
| Laboratory parameters | ||
| Total bilirubin (µmol/L) | 13 | (10‐20) |
| ALT (IU/l) | 42 | (27‐84) |
| AST (IU/l) | 38 | (27‐62) |
| ALP (IU/l) | 150 | (101‐234) |
| ×ULN ALP | 1.2 | (0.8‐1.8) |
| GGT (IU/L) | 123 | (49‐306) |
| Albumin (g/L) | 40 | (38‐42) |
| Prothrombin time (seconds) | 10.6 | (10.3‐11.0) |
| Platelet count (×109/L) | 254 | (193‐302) |
| Liver fibrosis markers | ||
| Liver stiffness (kPa) | 6.8 | (5.3‐10.0) |
| ELF score | 9.4 | (8.7‐9.9) |
| Prognostic risk models | ||
| MRS | 0.1 | (−0.2 to 0.5) |
| AOM score | 1.6 | (1.3‐2.1) |
Continuous variables are expressed as median (IQR) and nominal variables as absolute number (%).
Abbreviations: ALT, alanine aminotransferase; GGT, gamma‐glutamyltransferase; INR, international normalized ratio; UDCA, ursodeoxycholic acid.